CommercialCoverageMedium impact
08.02.41, Datopotamab deruxtecan (Datroway®)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Nov 3, 2025
We identified it
Jun 19, 2026
Summary
This is a NEW pharmacy policy for Datopotamab deruxtecan (Datroway®), effective November 3, 2025. The policy establishes coverage guidelines, prior authorization requirements, and billing protocols for this new oncology medication. Billing teams must implement this policy immediately to ensure proper claim submission and avoid denials.
Action Required
By November 3, 2025: Billing team must review the complete policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=11&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-02-41 to identify specific HCPCS J-codes, prior authorization requirements, and coverage criteria for Datroway® (Datopotamab deruxtecan). Update billing software with prior authorization rules and coverage limitations. Coordinate with providers and pharmacy to ensure prescriptions meet medical necessity requirements before claim submission. Train oncology and relevant clinical staff on new medication coverage and billing procedures. Failure to follow prior authorization requirements will result in claim denials.